RBC Europe’s Genomic Health, Inc. GHDX Stock Holding History

RBC Europe’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,924	Closed	-$130K	–	1080
2019 Q3	$130K	Sell	1,924 -11,576	-86%	-$795K	0.01%	293
2019 Q2	$785K	Buy	13,500 +3,500	+35%	+$207K	0.08%	128
2019 Q1	$701K	Hold	10,000	–	–	0.08%	133
2018 Q4	$644K	Sell	10,000 -3,000	-23%	-$210K	0.08%	128
2018 Q3	$913K	Sell	13,000 -5,000	-28%	-$292K	0.1%	114
2018 Q2	$907K	Sell	18,000 -4,500	-20%	-$179K	0.11%	118
2018 Q1	$704K	Buy	22,500 +2,000	+10%	+$66.4K	0.09%	133
2017 Q4	$701K	Hold	20,500	–	–	0.09%	129
2017 Q3	$658K	Buy	+20,500	New	+$647K	0.09%	131

RBC Europe's GHDX Position: Q4 2019 in Review

RBC Europe sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 1,924 shares — an estimated $130K sold.

RBC Europe first reported a position in GHDX in Q3 2017 and held it in 9 quarters. The position peaked at $913K in Q3 2018. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.

RBC Europe reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
RBC Europe sold 1,924 Genomic Health, Inc. shares in Q4 2019, an estimated $130K.
RBC Europe first reported a position in Genomic Health, Inc. in Q3 2017 and held it in 9 quarters.
RBC Europe's Genomic Health, Inc. position peaked at $913K in Q3 2018.
0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.

Based on RBC Europe's 13F filing for Q4 2019, filed 9 Nov 2023.